Русский

Pharmaceutical Industry Information Portal

HomeTagsNovavax

All posts by tag

Novavax

Novavax-logoNovavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases.

Prior to 2020, company scientists developed experimental vaccines for Ebola, influenza, respiratory syncytial virus (RSV), and other emerging infectious diseases.During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19. Novavax has indicated it recognizes a continued need for innovative vaccines in other therapeutic areas and reports it has taken steps to ensure continued advancement of its influenza vaccine.

World Pharma News

EC approves contract for a potential COVID-19 vaccine with Novavax

Techno -
Under this contract, Member States will be able to purchase up to 100 million doses of the Novavax vaccine, with an option for 100 million additional doses.
Discovery and Development

Novavax Covid-19 Vaccine demonstrates 90,4% Effective in Late-stage Trial

Techno -
Biotech company Novavax said that its COVID-19 vaccine is 90.4% effective in a late-stage trial of nearly 30,000 people in the U.S. and Mexico
12Page 2 of 2
spot_img

Expert Articles

spot_img

Information Internet project PharmProm.Net dedicated to the pharmaceutical industry in the world. It contains a contact base of organizations, enterprises, companies associated with the pharmaceutical market. The editorial staff of the PharmProm.Net portal offers cooperation in the field of information promotion and advertising in the pharmaceutical market.

Read our Russian-language online magazine

Categories